BofA/Merrill Lynch Downgrades Intercept (ICPT) to Neutral on Lack of Catalysts
Tweet
Share
E-mailGet Alerts ICPT Hot Sheet
Price: $19.00 --0%
Rating Summary:
13 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 22
Rating Summary:
13 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 22
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Buy to Neutral with a price target of $315. Earlier Intercept announced plans for an international Phase 3 trial of OCA in NASH. Analyst Ying Haung sees the design "as expected" though the trial size is larger. The downgrade was tied to a lack of catalysts going forward.
For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.
Shares of Intercept Pharmaceuticals closed at $313.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Principal Financial Group (PFG) to Underperform
- JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight
- Alimentation Couche-Tard Inc (ATD/B:CN) (ANCUF) PT Raised to Cdn$104 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Downgrades, Hot Comments, Hot Downgrades, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
